IRWD - Ironwood Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Boston,
United States
Type: Equity
IRWD price evolution
IRWD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $105.52 | $121.54 | $92.15 | |
| Short term investments | ||||
| Net receivables | $76.2 | $58.11 | $72.02 | $129.12 |
| Inventory | ||||
| Total current assets | $178.6 | $178.18 | $208.17 | $233.29 |
| Long term investments | ||||
| Property, plant & equipment | $16.23 | $16.89 | $17.5 | $18.17 |
| Goodwill & intangible assets | $3.27 | $3.48 | $3.68 | |
| Total noncurrent assets | $217.44 | $230.65 | $237.78 | |
| Total investments | ||||
| Total assets | $389.52 | $395.62 | $438.82 | $471.07 |
| Current liabilities | ||||
| Accounts payable | $3.24 | $3.23 | $6.22 | $7.83 |
| Deferred revenue | ||||
| Short long term debt | $3.16 | $202.94 | $202.69 | |
| Total current liabilities | $49.38 | $45.51 | $252.44 | $276.1 |
| Long term debt | $598.82 | $637.1 | $487.48 | $512.85 |
| Total noncurrent liabilities | $671.84 | $516.89 | $541.27 | |
| Total debt | $640.26 | $690.42 | $715.54 | |
| Total liabilities | $700.85 | $717.35 | $769.34 | $817.37 |
| Shareholders' equity | ||||
| Retained earnings | -$1699.99 | -$1703.64 | -$1702.78 | -$1698.62 |
| Other shareholder equity | -$2.05 | -$0.47 | -$0.92 | -$3.03 |
| Total shareholder equity | -$321.73 | -$330.52 | -$346.3 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $92.15 | $657.45 | $621.38 | $364.3 |
| Short term investments | ||||
| Net receivables | $129.12 | $115.46 | $138.04 | $145.75 |
| Inventory | ||||
| Total current assets | $233.29 | $780.63 | $745.23 | $495.84 |
| Long term investments | $0.48 | $0.48 | $0.48 | |
| Property, plant & equipment | $18.17 | $20.31 | $22.93 | $25.5 |
| Goodwill & intangible assets | $3.68 | |||
| Total noncurrent assets | $237.78 | $319.89 | $381.7 | $63.4 |
| Total investments | $0.48 | $0.48 | $0.48 | |
| Total assets | $471.07 | $1100.52 | $1126.93 | $559.24 |
| Current liabilities | ||||
| Accounts payable | $7.83 | $0.48 | $0.94 | $0.66 |
| Deferred revenue | ||||
| Short long term debt | $202.69 | $3.08 | $121.3 | $3.13 |
| Total current liabilities | $276.1 | $25.52 | $161.7 | $32.17 |
| Long term debt | $512.85 | $396.25 | $355.82 | $462.66 |
| Total noncurrent liabilities | $541.27 | $422.62 | $359.32 | $464.43 |
| Total debt | $715.54 | $415.93 | $477.12 | $465.79 |
| Total liabilities | $817.37 | $448.14 | $521.02 | $496.6 |
| Shareholders' equity | ||||
| Retained earnings | -$1698.62 | -$696.38 | -$937.61 | -$1466.06 |
| Other shareholder equity | -$3.03 | $605.91 | ||
| Total shareholder equity | -$346.3 | $652.38 | $605.91 | $62.64 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $91.59 | $94.4 | $74.88 | $117.55 |
| Cost of revenue | ||||
| Gross Profit | $94.4 | $74.88 | $117.55 | |
| Operating activities | ||||
| Research & development | $30.39 | $25.82 | $35.68 | |
| Selling, general & administrative | $36.96 | $37.6 | $38.67 | |
| Total operating expenses | $65.94 | $69.42 | $63.86 | $79.96 |
| Operating income | $24.98 | $11.02 | $37.59 | |
| Income from continuing operations | ||||
| EBIT | $26.35 | $12.19 | $39.44 | |
| Income tax expense | $13.72 | $19.74 | $9.12 | $32.1 |
| Interest expense | -$8.27 | $7.47 | $7.23 | $8.42 |
| Net income | ||||
| Net income | $3.65 | -$0.86 | -$4.16 | -$1.09 |
| Income (for common shares) | -$0.86 | -$4.16 | -$1.09 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $442.74 | $410.6 | $413.75 | $389.52 |
| Cost of revenue | $3.14 | |||
| Gross Profit | $442.74 | $410.6 | $413.75 | $386.39 |
| Operating activities | ||||
| Research & development | $116.08 | $44.27 | $70.41 | $88.06 |
| Selling, general & administrative | $158.31 | $115.99 | $111.13 | $140 |
| Total operating expenses | $1388.16 | $160.26 | $181.49 | $243.45 |
| Operating income | -$945.43 | $250.34 | $232.26 | $142.94 |
| Income from continuing operations | ||||
| EBIT | -$897.12 | $260.02 | $231.81 | $138.34 |
| Income tax expense | $83.49 | $77.36 | -$327.79 | $2.69 |
| Interest expense | $21.63 | $7.6 | $31.15 | $29.48 |
| Net income | ||||
| Net income | -$1002.24 | $175.06 | $528.45 | $106.18 |
| Income (for common shares) | -$1002.24 | $175.06 | $528.45 | $106.18 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$0.86 | -$4.16 | -$1.09 | |
| Operating activities | ||||
| Depreciation | $0.51 | $0.51 | $0.51 | |
| Business acquisitions & disposals | -$3.98 | |||
| Stock-based compensation | $8.57 | $8.38 | $8.7 | |
| Total cash flows from operations | $33.47 | $44.98 | $35.83 | |
| Investing activities | ||||
| Capital expenditures | -$0.06 | -$0.07 | -$0.21 | |
| Investments | ||||
| Total cash flows from investing | -$0.14 | -$0.06 | -$0.07 | -$4.19 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.75 | $10.06 | $1 | |
| Net borrowings | -$50 | -$25 | -$25.59 | |
| Total cash flows from financing | -$92.08 | -$49.37 | -$15.55 | -$50.9 |
| Effect of exchange rate | -$0.05 | -$0.05 | $0.02 | -$0.05 |
| Change in cash and equivalents | -$3.94 | -$16.02 | $29.39 | -$19.31 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$1002.24 | $175.06 | $528.45 | $106.18 |
| Operating activities | ||||
| Depreciation | $1.57 | $1.42 | $1.52 | $3.56 |
| Business acquisitions & disposals | -$1026.05 | |||
| Stock-based compensation | $32.01 | $27.05 | $22.28 | $31.18 |
| Total cash flows from operations | $183.43 | $273.76 | $261.89 | $168.84 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.14 | -$0.27 | -$1.84 |
| Investments | ||||
| Total cash flows from investing | -$1026.32 | -$0.14 | -$0.27 | -$1.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.36 | -$116.85 | -$4.55 | $18.55 |
| Net borrowings | $297.11 | -$120.7 | ||
| Total cash flows from financing | $277.16 | -$237.55 | -$4.55 | $18.55 |
| Effect of exchange rate | -$0.05 | |||
| Change in cash and equivalents | -$565.78 | $36.07 | $257.08 | $185.54 |
News
Fundamentals
| Market cap | $307.23M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 160.02M |
| Revenue | $378.42M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$2.46M |
| Revenue Q/Q | -19.47% |
| Revenue Y/Y | -12.48% |
| P/E ratio | -124.74 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.81 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.02 |
|---|---|
| ROA | -0.58% |
| ROE | N/A |
| Debt/Equity | -2.36 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.62 |
| Quick ratio | N/A |